Lv7
5000 积分 2024-06-26 加入
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer
7天前
已完结
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer
7天前
已完结
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
18天前
已完结
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
1个月前
已完结
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
2个月前
已完结
Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
2个月前
已完结
Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials
2个月前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
3个月前
已完结
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression
3个月前
已完结
MA01.05 Tislelizumab Plus Chemotherapy Followed by Surgery or Radiotherapy and Adjuvant Tislelizumab in Unresectable Stage III NSCLC
3个月前
已完结
皖公网安备34019202002308
